ERBB2 and breast carcinoma: Furthermore, (iii), can we establish a unified model of ERBB signaling for the luminal, TNBC and HER2-positive cell-line systems that is able to predict the effect of ligand stimulation and drug treatments for the three breast cancer subtypes?